News | Wearables | December 07, 2022

University of Missouri Researchers Design New Heart Health Wearable

Using a $2.6 million grant from NIH, researchers at the MU College of Engineering are designing a breathable material with antimicrobial properties for use with a wearable heart monitor. 

Brian Arends, left, checks the electrical resistivity and conductivity of the wearable heart monitor as Zheng Yan, center, and Yadong Xu, right, observe in Yan's lab. The lab is located in the Roy Blunt NextGen Precision Health building. Pate McCuien/University of Missouri

Brian Arends, left, checks the electrical resistivity and conductivity of the wearable heart monitor as Zheng Yan, center, and Yadong Xu, right, observe in Yan's lab. The lab is located in the Roy Blunt NextGen Precision Health building. Pate McCuien/University of Missouri 

 


December 7, 2022 —  While heart disease is a leading cause of death in the United States, most people can be treated with early detection and timely interventions. That’s why Zheng Yan and a team of researchers at the University of Missouri are using a $2.6 million grant from the National Institutes of Health (NIH) to help create a breathable material — with antibacterial and antiviral properties — to support the team’s ongoing development of a multifunctional, wearable heart monitor. 

The wearable device is designed to continuously track the health of a human heart via dual signals simultaneously — an electrocardiogram (ECG), which measures a heart’s electrical signal, and a seismocardiogram (SCG), which measures heart vibrations. After these signals are recorded on an electronic device, this information could be shared with a person’s healthcare provider to help identify potential warning signs related to heart disease. 

Yan, an assistant professor in the Department of Biomedical, Biological and Chemical Engineering and the Department of Mechanical and Aerospace Engineering, said the device is designed for use in personalized health care. 

“We want to provide comprehensive information about the status of a person’s heart,” Yan said. “Effects of heart disease can often happen unexpectedly, so it’s important to have continuous, long-term monitoring for early detection and timely interventions. We want this to help reduce the number of people succumbing to death from heart disease in the U.S.” 

Since the breathable material encompasses the device and may potentially stay attached to a person’s skin for at least a couple weeks, or even up to one month, Yan said the material’s integrated antibacterial and antiviral properties can help prevent the accumulation of harmful bacteria and viruses from forming on the surface of a person’s skin underneath the device itself. 

The material’s breathability is also designed to help mitigate the loss of an accurate signal when a person sweats. Another benefit is the material’s ultra-soft properties, Yan said. 

“Under the microscope, our skin is not flat,” Yan said. “So, an ultra-soft material can form what we call a conformal contact, which is very important for us in order to have a high level of accuracy for our signal recording of the electrical activity of the human heart.” 

Similar devices in existence today typically only monitor the human heart via an ECG, and have limited long-term use, Yan said. Currently the device is a small, wired patch connected to a small data processor that can be attached to a person’s shirt, and researchers hope to one day develop a wireless version. 

The project, “Multifunctional Porous Soft Materials for User-Friendly Skin-Interfaced Bimodal Cardiac Patches with Long-Term Biocompatibility and Antimicrobial Property” is being supported by the National Institutes of Health (1-R01-EB033371-01). 

For more information: https://showme.missouri.edu/schools-colleges/mu-college-of-engineering/ 


Related Content

News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
Subscribe Now